| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Supira Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $241.09M | Series E | 3/26/2025 | $120M | $431.99M | $1.35 | Novo Holdings, Qatar Investment Authority, Cormorant Asset Management, TCP, 415 Capital, AMED Ventures, Picard Angst, Unorthodox Ventures | ||||
 | Tune Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $223.37M | Series B-1 | 1/13/2025 | $61.49M | $355.58M | $1.20 | New Enterprise Associates, Yosemite, Regeneron Ventures, Hevolution Foundation | ||||
 | Ultima Genomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Vedanta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.86M | Series B-1 | 8/6/2026 | $22.57M | $113.87M | $0.17 | AMR Action Fund, BNP Paribas | ||||
 | BigHat Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $228.41M | Series C | 7/13/2026 | $80M | $452.43M | $10.01 | Undisclosed Investors | ||||
 | Evozyne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.19M | Series B | 9/27/2023 | $50M | $288.32M | $15.49 | Fidelity Management & Research Company, OrbiMed, NVentures, Paragon Biosciences, Valor Equity Partners | ||||
 | Exo | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $43.94M | Series D | 5/28/2025 | $22.09M | $272.82M | $0.86 | Samsung, Sands Capital, Bold Capital, Qubit Health Capital | ||||
 | HALO Precision Diagnostics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $1.05M | -- | 1 | Not available | -- | -- | $173.71M | Series C-2 | 4/11/2025 | $27.95M | $293.85M | $0.81 | Undisclosed Investors | ||||
 | HealthVerity | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $254.63M | Series E | 5/8/2026 | $112.37M | $977.03M | $21.47 | Undisclosed Investors | ||||
 | Kumquat Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $135.92M | Series A-2 | 7/28/2021 | $30M | $494.98M | $10.32 | Undisclosed Investors | ||||
 | Medely | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $134.93M | Series C | 3/15/2022 | $90M | $735.36M | $32.61 | General Catalyst, Mayhaw Capital | ||||
 | Mission Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $183M | Series B-1 | 8/5/2025 | $40M | $210.45M | $1.00 | Ally Bridge Group | ||||
 | Neumora | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $612.4M | Series B | 10/11/2022 | $112.4M | $1.33B | $1.50 | Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners | ||||
 | Synthego | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $415.07M | Series E | 2/17/2022 | $144.17M | $1.3B | $10.78 | Perceptive Advisors, SoftBank, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund, Chimera Abu Dhabi, Wellington Management, RA Capital Management, Moore Strategic Ventures | ||||
 | Verge Genomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $167.53M | Series C* | 9/8/2023 | $42M | $403.75M | $7.19 | Alexion, AstraZeneca, Alumni Ventures, Tenmile | ||||
 | Verily Life Sciences | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Wheel | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $176.35M | Series C | 1/19/2022 | $125M | $984.27M | $37.49 | Lightspeed Venture Partners, Tiger Global Management, Coatue Management, Salesforce Ventures, CRV, Tusk Venture Partners, Silverton Partners | ||||
 | Be Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $274.72M | Series C | 1/15/2025 | $92.62M | $154.23M | $2.90 | ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures, Nextech | ||||
 | BioAge | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.42B | Series D | 2/13/2024 | $170M | $440.23M | $3.42 | Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz | ||||
 | ClevelandDx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $117.45M | Series E-2 | 10/7/2025 | $26.99M | $330.17M | $4.99 | Novo Holdings | ||||
 | Cordis | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $156.00K | -- | 1 | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Favor | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.55M | Series B-2 | 6/14/2021 | $41.98M | $408.74M | $2.19 | Base10, ACME, GV, Shasta Ventures, VMG, Dara Khosrowshahi, George Ruan, iGlobe | ||||
 | Grail | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $2.02B | Series D | 5/6/2020 | $392.01M | $4.26B | $5.11 | Public Sector Pension Investment Board, Canada Pension Plan Investment Board, Illumina | ||||
 | Iterative Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $272.32M | Series C | 4/30/2026 | $77.01M | $1.3B | $26.32 | Intrepid Growth Partners, GV, EDBI, Insight Partners, Obvious Ventures | ||||